Kanada - enska - Health Canada

leo pharma gen, a division of leo pharma inc. - tacrolimus - ointment - 0.1% - tacrolimus 0.1%

Kanada - enska - Health Canada

leo pharma gen, a division of leo pharma inc. - tacrolimus - ointment - 0.03% - tacrolimus 0.03%

Ísrael - enska - Ministry of Health

megapharm ltd - bleomycin sulfate - powder for solution for injection - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Írland - enska - HPRA (Health Products Regulatory Authority)

leo pharma a/s - protamine sulphate - solution for injection/infusion - 1400 international unit(s)/millilitre - antidotes; protamine

Malta - enska - Medicines Authority

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - protamine sulfate - solution for injection/infusion - protamine sulfate 10 mg/ml - all other therapeutic products

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: = squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). = squamous cell carcinoma of the larynx, penis and uterine cervix. = squamous cell carcinoma of the bronchus (response infrequent). = choriocarcinoma and embryonal cell carcinoma of the testis. = advanced hodgkin's disease and other lymphomas. = mycosis fungoides.,note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

leo pharma limited - diflucortolone valerate 0.1% - topical cream - 0.1 % - active: diflucortolone valerate 0.1% excipient: carbomer disodium edetate dihydrate liquid paraffin macrogol stearate 2000 methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium hydroxide stearyl alcohol white soft paraffin - all skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

leo pharma limited - diflucortolone valerate 0.1% - topical ointment - 0.1 % - active: diflucortolone valerate 0.1% excipient: hydrogenated castor oil liquid paraffin microcrystalline wax white soft paraffin - all skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

leo pharma limited - ingenol mebutate 0.015%{relative} ((70 µg per tube)) - topical gel - 0.015% w/w - active: ingenol mebutate 0.015%{relative} ((70 µg per tube)) excipient: benzyl alcohol citric acid monohydrate hyetellose isopropyl alcohol purified water sodium citrate dihydrate - topical treatment of solar (actinic) keratoses in adults

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

leo pharma limited - ingenol mebutate 0.05%{relative} ((235 µg per tube)) - topical gel - 0.05% w/w - active: ingenol mebutate 0.05%{relative} ((235 µg per tube)) excipient: benzyl alcohol citric acid monohydrate hyetellose isopropyl alcohol purified water sodium citrate dihydrate - topical treatment of solar (actinic) keratoses in adults